 Esperion Therapeutics Incs NASDAQ: ESPR cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a year. What Happened: The Company says it will cut about 40 of its staff over the next few weeks, or approximately 170 staffers are on the chopping block. 